Navigation Links
WuXi PharmaTech (NYSE: WX) Names Temporary Chairman of the Audit Committee
Date:1/6/2008

SHANGHAI, China, Jan. 6 /Xinhua-PRNewswire/ -- WuXi PharmaTech (NYSE: WX), China's premier provider of pharmaceutical R&D outsourcing services, announced today that Mr. Cuong Viet Do will temporarily assume the role of the Chairman of the Audit Committee until a permanent successor is appointed.

The Chairman of the Audit Committee was previously held by Mr. Shawn Wang who recently passed away in an accident during his vacation.

Mr. Cuong Viet Do has served as an independent director on WuXi PharmaTech's Board of Directors since July 2007 and is a member of the Audit Committee. Mr. Do is currently the chief strategy officer of Lenovo Group Limited. Mr. Do joined Lenovo in 2006 after 17 years at McKinsey & Company, where he was Director and senior partner. During his tenure at McKinsey, he consulted with leading companies in 18 countries and four continents on issues involving strategy, sales and marketing, operations, and corporate finance. Mr. Do was a leader of McKinsey's Corporate Finance practice and was responsible for training all of McKinsey's consultants on Finance and M&A topics. At different stages of his career at McKinsey, Mr. Do helped build and was a leader in the healthcare, high tech, and marketing practices. Mr. Do has more than a decade experience working with pharmaceutical and medical device companies around the world in R&D, sales and marketing, licensing & acquisitions, and operations. He has also served hospitals and governments on healthcare policy.

Mr. Do has a bachelor's degree in Biochemistry and Economics from Dartmouth College and a master's degree in Business Administration from the Tuck School of Business Administration, where he now serves on the MBA Board. He also serves on the boards of several non-profit groups, including Celebrate the Children, a school for autistic children, and the National Youth Science Foundation.

About WuXi PharmaTech

Founded in 2000, Shanghai-based WuXi PharmaTech is the leading China-based pharmaceutical and biotechnology R&D outsourcing company. As a research- driven and customer-focused company, WuXi PharmaTech provides pharmaceutical and biotechnology companies a broad and integrated portfolio of laboratory and research manufacturing services throughout the drug discovery and development process. WuXi PharmaTech's services are designed to assist its global partners in shortening the cycle and lowering the cost of drug discovery and development by providing cost-effective and efficient outsourcing solutions that save its customers both time and money. Its operations are grouped into two segments: laboratory services, consisting of discovery chemistry, service biology, analytical, toxicology, pharmaceutical development and process development services, and research manufacturing, focusing on manufacturing of advanced intermediates and active pharmaceutical ingredients for R&D use. In 2007, its 80 customers included nine of the world's top ten pharmaceutical companies by revenue. For more information, please visit: http://www.wuxipharmatech.com .

For more information, please contact:

Sherry Shao

Tel: +86-21-5046-4002

Email: pr@pharmatechs.com


'/>"/>
SOURCE WuXi PharmaTech
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. WuXi PharmaTech Schedules 2007 Third Quarter Earnings Release on Monday, November 12, 2007
2. WuXi PharmaTech (NYSE: WX) CEO Honored with Ernst & Young Entrepreneur Of The Year China 2007 Award
3. WuXi PharmaTech Announces Third Quarter 2007 Results
4. WestChina-Frontier PharmaTech Awarded Full AAALAC Accreditation
5. WuXi PharmaTech (NYSE: WX) Mourns the Tragic Loss of Its Independent Director Shawn Wang
6. ResMed Names Kieran Gallahue as Chief Executive Officer, Effective January 1, 2008.
7. Mediware Names Thomas K. Mann Chief Executive Officer
8. Cleveland-based Health Care Tech Company Within3 Names New CEO
9. STERIS Corporation Board of Directors Names Walter M. Rosebrough Jr. President and Chief Executive Officer
10. Patient Safety Authority Board of Directors Names Infection Advisory Panel
11. Hooper Holmes Names Chris Behling President of Health & Wellness Division
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... , ... June 26, 2016 , ... Pixel Film Studios ... X. , "Film editors can give their videos a whole new perspective by using ... - CEO of Pixel Film Studios. , ProSlice Levels contains over 30 Different ...
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from the American Institutes ... Research Meeting June 26-28, 2016, at the Hynes Convention Center in Boston. , ... advance care planning, healthcare costs and patient and family engagement. , AIR researchers ...
(Date:6/25/2016)... TX (PRWEB) , ... June 25, 2016 , ... ... the United States, named Dr. Sesan Ogunleye, as the Medical Director of its new ... the facility Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits ... terms of the latter, setting the bar too high can result in disappointment, perhaps ... slow progress toward their goal. , Research from PsychTests.com reveals that ...
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, was out ... family verbally and physically. , “When something upset him, he couldn’t control his emotions,” remembers ... would throw rocks at my other children and say he was going to kill them. ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Belgium , June 24, 2016 /PRNewswire/ ... announced the appointment of Dr. Edward Futcher ... a Non-Executive Director, effective June 23, 2016.Dr. Futcher ... and Nominations and Governance Committees.  As a non-executive ... provide independent expertise and strategic counsel to VolitionRx ...
(Date:6/23/2016)... 2016 Research and Markets has ... by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), ... Parenteral) - Global Forecast to 2021" report to ... The global pharmaceutical excipients market is projected to reach ... 6.1% in the forecast period 2016 to 2021. ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... "Key Pharma News Issue 52" report to their offering. ... need in influenza treatment creates a favourable commercial environment for ... and growing patient base that will serve to drive considerable ... flu vaccine would serve to cap sales considerably, but development ...
Breaking Medicine Technology: